BBIO — BridgeBio Pharma, Inc.
3 mentions in the last 24 hours · 0.01% of all mentions
Why people talked about BBIO (2026-10-30)
- BridgeBio Pharma reported Q3 2026 financial results, with revenue of $353.2M beating estimates and a narrowed operating loss due to a $75M milestone payment from Bayer.
- The company announced Q3 2026 earnings per share of -$0.42, which exceeded analyst estimates, while US sales of the heart drug Attruby reached $253M.
- Recent business updates and financial results for the quarter ended September 30, 2026, were officially disclosed via a press release and earnings call transcript.
| RSS Bundle | 2 | news |
| Marketaux | 1 | news |
| Bluesky | 0 | community |
| SEC EDGAR 8-K | 0 | filings |